BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

22 related articles for article (PubMed ID: 38537579)

  • 1. Zinc-chelating BET bromodomain inhibitors equally target islet endocrine cell types.
    Jones Lipinski RA; Stancill JS; Nuñez R; Wynia-Smith SL; Sprague DJ; Nord JA; Bird A; Corbett JA; Smith BC
    Am J Physiol Regul Integr Comp Physiol; 2024 Jun; 326(6):R515-R527. PubMed ID: 38618911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCL7 Chemokine Is a Marker but Not a Therapeutic Target of Acute Kidney Injury.
    Casemayou A; Piedrafita A; Engel R; Feuillet G; Alves M; Tack I; Klein J; Buleon M; Schanstra JP; Faguer S
    Nephron; 2024; 148(6):437-442. PubMed ID: 38281481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil-derived nanovesicles deliver IL-37 to mitigate renal ischemia-reperfusion injury via endothelial cell targeting.
    Ma W; Wu D; Long C; Liu J; Xu L; Zhou L; Dou Q; Ge Y; Zhou C; Jia R
    J Control Release; 2024 Jun; 370():66-81. PubMed ID: 38631490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precisely targeted drug delivery by mesenchymal stem cells-based biomimetic liposomes to cerebral ischemia-reperfusion injured hemisphere.
    Dong YF; Li YS; Liu H; Li L; Zheng JJ; Yang ZF; Sun YK; Du ZW; Xu DH; Li N; Jiang XC; Gao JQ
    J Control Release; 2024 Jun; ():. PubMed ID: 38851537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage.
    Suarez-Alvarez B; Morgado-Pascual JL; Rayego-Mateos S; Rodriguez RM; Rodrigues-Diez R; Cannata-Ortiz P; Sanz AB; Egido J; Tharaux PL; Ortiz A; Lopez-Larrea C; Ruiz-Ortega M
    J Am Soc Nephrol; 2017 Feb; 28(2):504-519. PubMed ID: 27436852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRD4 suppression alleviates cerebral ischemia-induced brain injury by blocking glial activation via the inhibition of inflammatory response and pyroptosis.
    Zhou Y; Gu Y; Liu J
    Biochem Biophys Res Commun; 2019 Nov; 519(3):481-488. PubMed ID: 31530390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brd4 inhibition attenuates unilateral ureteral obstruction-induced fibrosis by blocking TGF-β-mediated Nox4 expression.
    Zhou B; Mu J; Gong Y; Lu C; Zhao Y; He T; Qin Z
    Redox Biol; 2017 Apr; 11():390-402. PubMed ID: 28063381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic targeting of BET protein BRD4 delays murine lupus.
    Wei S; Sun Y; Sha H
    Int Immunopharmacol; 2015 Dec; 29(2):314-319. PubMed ID: 26590112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BET bromodomain inhibition of MYC-amplified medulloblastoma.
    Bandopadhayay P; Bergthold G; Nguyen B; Schubert S; Gholamin S; Tang Y; Bolin S; Schumacher SE; Zeid R; Masoud S; Yu F; Vue N; Gibson WJ; Paolella BR; Mitra SS; Cheshier SH; Qi J; Liu KW; Wechsler-Reya R; Weiss WA; Swartling FJ; Kieran MW; Bradner JE; Beroukhim R; Cho YJ
    Clin Cancer Res; 2014 Feb; 20(4):912-25. PubMed ID: 24297863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BET inhibitor nanotherapy halts kidney damage and reduces chronic kidney disease progression after ischemia-reperfusion injury.
    Saiz ML; Lozano-Chamizo L; Florez AB; Marciello M; Diaz-Bulnes P; Corte-Iglesias V; Bernet CR; Rodrigues-Diez RR; Martin-Martin C; Rodriguez-Santamaria M; Fernandez-Vega I; Rodriguez RM; Diaz-Corte C; Suarez-Alvarez B; Filice M; Lopez-Larrea C
    Biomed Pharmacother; 2024 May; 174():116492. PubMed ID: 38537579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BET bromodomain inhibitors--a novel epigenetic approach in castration-resistant prostate cancer.
    Lochrin SE; Price DK; Figg WD
    Cancer Biol Ther; 2014; 15(12):1583-5. PubMed ID: 25535892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JQ1: a novel potential therapeutic target.
    Shi X; Liu C; Liu B; Chen J; Wu X; Gong W
    Pharmazie; 2018 Sep; 73(9):491-493. PubMed ID: 30223929
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.